![]() |
市場調查報告書
商品編碼
2081551
乳房攝影影像市場:按產品、技術、設備類型、類別、影像方法、應用和最終用戶分類-2026-2032年全球市場預測Breast Imaging Market by Product, Technology, Equipment Type, Category, Imaging Modality, Application, End-User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,乳房攝影影像市場將成長至 103.5 億美元,複合年成長率為 8.52%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 58.3億美元 |
| 預計年份:2026年 | 63.1億美元 |
| 預測年份 2032 | 103.5億美元 |
| 複合年成長率 (%) | 8.52% |
乳房攝影影像在乳癌的早期發現、診斷、治療方案製定和後續觀察中發揮著至關重要的作用。根據世界衛生組織(WHO)和國際癌症研究機構(IARC)統計,乳癌仍是全球最常見的癌症之一,2022年報告的新病例約230萬例,死亡病例約67萬例。這種持續的臨床負擔推動了對乳房X光攝影、數位乳房斷層合成、乳房超音波、乳房磁振造影、造影乳房X光乳房X光攝影、切片檢查引導和影像分析的需求。
由於2D篩檢乳房X光攝影向數位乳房斷層合成的轉變、超音波和磁振造影在高密度乳房組織中的輔助應用日益廣泛,以及造影乳房X光乳房X光攝影臨床應用的不斷擴展,乳房攝影影像領域正在經歷一場變革。有關乳房密度告知、個人化篩檢間隔和基於風險的影像檢查路徑的監管和臨床指南也在不斷發展改進。
人工智慧 (AI) 已不再只是單一功能的附加組件,它正逐漸對整體乳房攝影影像領域產生累積影響。同行評審的研究表明,AI 可以輔助病灶檢測、減少特定工作流程中的假陽性結果、優先處理可疑檢查,並幫助評估乳房密度。最具商業性價值的應用包括:AI 在乳房乳房X光攝影攝影和斷層合成影像判讀中的應用、乳房超音波的自動閱片、MRI影像分割、風險評分、影像品質評估和品管。
由於完善的篩檢項目、數位乳房乳房X光攝影的廣泛應用、FDA監管的乳房X光攝影品質標準以及數位乳房斷層合成技術的日益普及,北美地區在乳房攝影影像檢查方面仍保持著較高的普及率。尤其值得一提的是,美國在這方面發揮著舉足輕重的作用,其乳房密度報告要求、保險報銷趨勢、認證標準以及私營部門的創新正在加速先進檢測方法和人工智慧驅動的工作流程工具的普及。在加拿大,省級篩檢計畫的系統實施、以品質為中心的放射學以及診斷成像能力的持續現代化進一步提升了該地區的普及率。
歐盟在系統性乳癌篩檢方面發揮政策和品質標竿的主導作用,制定循證建議,支持系統性篩檢計畫、標準化績效監測、品質保證和後續追蹤路徑。七國集團(G7)憑藉著成熟的保險報銷體系、高度的臨床意識、完善的放射學基礎設施以及對人工智慧、斷層合成、乳房磁振造影和基於風險的評估方法的早期應用,引領著最尖端科技的應用。北約成員國的市場與許多先進的醫療保健系統重疊,這強化了其在採購中對互通性、網路安全、資料管治、雲端彈性以及彈性成像基礎設施的重視。
美國在先進乳房攝影影像技術的應用方面處於主導地位,這得益於乳房X光檢查的普及、數位乳房斷層合成技術的快速發展、人工智慧的法規核准和認證要求,以及全美民眾對乳房密度的關注。加拿大透過省級計畫和以品質為導向的放射學,維持著一套完善的篩檢體系。同時,墨西哥正透過公共醫療機構、私人影像中心和腫瘤轉診網路,擴大診斷服務的覆蓋範圍。巴西仍然是拉丁美洲領先的乳房影像市場,這得益於其對乳房攝影防控的重視、私人診斷服務的擴張,以及都市區對乳房超音波、超音波檢查、切片檢查成像和磁振造影的需求。
產業供應商應優先考慮經臨床檢驗的乳房攝影,這些方案能夠提高放射科醫生的工作效率,減少複查差異,支持早期癌症篩檢,並實現基於風險的篩檢。產品策略應整合數位乳房X光乳房X光攝影、斷層合成、超音波、磁振造影、造影超音波乳房X光乳房X光攝影、切片檢查引導和人工智慧等技術,並建立可與PACS、RIS、EHR、病理系統和腫瘤資訊系統整合的互通性工作流程。
本執行摘要基於來自經認可的公共衛生、監管和臨床來源的已驗證的二手研究,包括世界衛生組織 (WHO)、國際癌症研究機構全球癌症觀察站、美國食品藥物管理局(FDA) 的乳腺X光攝影品質材料、美國預防服務工作組 (USPSTF) 的指南、美國乳癌照相院 (ACR) 的攝影資訊來源、美國預防服務工作組 (檢驗) .
乳房攝影影像學正步入一個以早期檢測、個人化篩檢、自動化工作流程和整合診斷路徑為特徵的新階段。乳癌持續肆虐,加上放射科醫師短缺以及人們對精準醫療日益成長的期望,使得對先進影像系統、智慧軟體和協作式乳房診療平台的需求持續成長。
The Breast Imaging Market is projected to grow by USD 10.35 billion at a CAGR of 8.52% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 5.83 billion |
| Estimated Year [2026] | USD 6.31 billion |
| Forecast Year [2032] | USD 10.35 billion |
| CAGR (%) | 8.52% |
Breast imaging is central to early breast cancer detection, diagnostic workup, treatment planning, and surveillance. According to the World Health Organization and IARC, breast cancer remains one of the most commonly diagnosed cancers worldwide, with approximately 2.3 million new cases and about 670,000 deaths reported in 2022. This sustained clinical burden is driving demand for mammography, digital breast tomosynthesis, breast ultrasound, breast MRI, contrast-enhanced mammography, biopsy guidance, and image analytics.
For technology vendors, equipment manufacturers, and breast imaging solution providers, growth is increasingly tied to measurable improvements in cancer detection, workflow productivity, radiation dose optimization, patient comfort, interoperability, and AI-enabled decision support. The breast imaging landscape is shifting from standalone imaging hardware toward integrated breast care platforms that connect acquisition, interpretation, reporting, risk assessment, navigation, pathology correlation, and longitudinal follow-up.
The breast imaging landscape is being reshaped by the transition from 2D screening mammography to digital breast tomosynthesis, the wider adoption of supplemental ultrasound and MRI for dense breast tissue, and the clinical expansion of contrast-enhanced mammography. Regulatory and clinical guidance continues to evolve around breast density notification, personalized screening intervals, and risk-adapted imaging pathways.
At the same time, healthcare systems are under pressure to reduce missed cancers, shorten report turnaround times, and manage radiologist shortages. These shifts are increasing demand for automated image triage, structured reporting, cloud-based archiving, quality assurance tools, dose monitoring, and enterprise imaging integration. Vendors that align product roadmaps with evidence-based screening, reimbursement requirements, regulatory expectations, and radiology workflow constraints are positioned to capture higher-value opportunities.
Artificial intelligence is becoming a cumulative force across breast imaging rather than a single-feature add-on. Peer-reviewed studies have shown that AI can support lesion detection, reduce false positives in specific workflows, prioritize suspicious exams, and assist with breast density assessment. The most commercially relevant applications include AI for mammography and tomosynthesis interpretation, automated breast ultrasound review, MRI segmentation, risk scoring, image quality assessment, and quality control.
The strongest AI adoption is expected where algorithms are embedded into radiologists' existing worklists and validated across diverse populations, scanner types, imaging protocols, and breast densities. Industry vendors must emphasize clinical validation, transparent performance reporting, cybersecurity, regulatory compliance, bias monitoring, and human-in-the-loop design. As AI matures, competitive advantage will depend on longitudinal learning systems that connect screening outcomes, pathology, prior imaging, genetics where appropriate, and patient risk data.
North America remains a high-adoption region for breast imaging due to established screening programs, broad installed bases of digital mammography, FDA-regulated mammography quality standards, and growing use of digital breast tomosynthesis. The United States is particularly influential because breast density notification requirements, reimbursement dynamics, accreditation standards, and private-sector innovation accelerate uptake of advanced modalities and AI-enabled workflow tools. Canada further strengthens regional adoption through organized provincial screening programs, quality-focused radiology practice, and ongoing modernization of diagnostic imaging capacity.
Europe benefits from organized population-based screening programs and strong quality assurance frameworks, particularly within the European Union, where evidence-based breast cancer screening recommendations and performance monitoring support standardized care pathways. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in cancer screening capacity, private diagnostic infrastructure, oncology programs, and advanced imaging technologies. Latin America is progressing through public-private diagnostic networks and cancer control initiatives in countries such as Brazil and Mexico, while the Middle East is supported by hospital investment, national health transformation plans, and growing screening awareness. Africa presents significant long-term need as governments and providers address gaps in access, trained radiology staff, screening participation, diagnostic follow-up, and equitable cancer care delivery.
The European Union is a leading policy and quality benchmark for organized breast cancer screening, with evidence-based recommendations supporting structured programs, standardized performance monitoring, quality assurance, and follow-up pathways. G7 markets drive premium technology adoption through mature reimbursement systems, high clinical awareness, established radiology infrastructure, and early integration of AI, tomosynthesis, breast MRI, and risk-based assessment approaches. NATO-aligned markets overlap with many advanced healthcare systems, reinforcing procurement priorities around interoperability, cybersecurity, data governance, cloud resilience, and resilient imaging infrastructure.
ASEAN and BRICS economies represent large population-driven opportunities where breast cancer incidence, urbanization, awareness campaigns, and private healthcare investment are increasing demand for scalable diagnostic capacity. Within ASEAN, expanding hospital networks and digital health initiatives support gradual adoption of mammography, ultrasound, and referral-based oncology pathways. BRICS countries combine large patient populations with ongoing public health investment and domestic imaging capabilities, creating demand for cost-effective, high-throughput solutions. GCC countries are prioritizing cancer care modernization through hospital investment, screening initiatives, women's health programs, and digital health adoption, making workflow efficiency, patient experience, and enterprise connectivity increasingly important.
The United States leads in advanced breast imaging adoption, supported by widespread mammography access, digital breast tomosynthesis penetration, AI regulatory clearances, accreditation requirements, and national attention to breast density. Canada maintains strong screening infrastructure through provincial programs and quality-oriented radiology practice, while Mexico is expanding diagnostic access through public providers, private imaging centers, and oncology referral networks. Brazil remains a major Latin American breast imaging market, supported by cancer control priorities, expanding private diagnostics, and demand for mammography, ultrasound, biopsy guidance, and MRI in urban centers.
The United Kingdom, Germany, France, Italy, and Spain benefit from organized screening programs, advanced radiology capabilities, and established cancer pathways, although workforce shortages, waiting times, and budget constraints influence procurement decisions. Germany and France continue to emphasize quality assurance and advanced diagnostic capability; the United Kingdom focuses on screening efficiency and service capacity; Italy and Spain combine regional screening structures with growing interest in tomosynthesis and supplemental imaging. Russia remains a sizable imaging market with localized procurement dynamics, hospital modernization needs, and demand for oncology diagnostics despite operational and supply-chain complexities.
China is scaling breast imaging through hospital modernization, expanding oncology infrastructure, public health awareness, and domestic manufacturing capabilities, while India offers strong long-term potential as awareness, insurance coverage, women's health initiatives, and diagnostic networks expand across urban and semi-urban areas. Japan, South Korea, and Australia are mature, quality-focused markets with strong adoption of advanced imaging and population health approaches. Japan emphasizes high-quality diagnostic workflows and ultrasound use, South Korea benefits from technology-forward healthcare delivery and screening participation, and Australia supports organized screening, dense-breast awareness, and evidence-based imaging pathways.
Industry vendors should prioritize clinically validated breast imaging solutions that improve radiologist productivity, reduce recall variability, support early cancer detection, and enable risk-adapted screening. Product strategies should combine digital mammography, tomosynthesis, ultrasound, MRI, contrast-enhanced mammography, biopsy guidance, and AI into interoperable workflows that integrate with PACS, RIS, EHR, pathology systems, and oncology information systems.
Commercial teams should build region-specific value propositions around reimbursement, screening policy, breast density legislation, accreditation requirements, workforce capacity, and infrastructure readiness. Vendors should also invest in service models, clinical training, remote support, cybersecurity, data privacy, lifecycle maintenance, and outcome-based evidence generation. Partnerships with cancer centers, academic radiology groups, public screening programs, and women's health networks will be essential for credibility, validation, and market access.
The executive summary is based on verified secondary research from recognized public health, regulatory, and clinical sources, including the World Health Organization, IARC Global Cancer Observatory, U.S. FDA mammography quality resources, U.S. Preventive Services Task Force guidance, American College of Radiology materials, European breast screening guidance, national cancer control resources, and peer-reviewed literature on breast imaging and AI.
The analysis synthesizes epidemiology, screening policy, technology adoption patterns, reimbursement considerations, modality trends, regulatory factors, workforce dynamics, and regional healthcare infrastructure indicators. Insights are structured to support market positioning while maintaining evidence-based accuracy and avoiding unverified market-size, market-share, or forecasting claims.
Breast imaging is entering a new phase defined by earlier detection, personalized screening, workflow automation, and integrated diagnostic pathways. The continued burden of breast cancer, combined with radiology workforce constraints and rising expectations for precision care, is creating sustained demand for advanced imaging systems, intelligent software, and connected breast care platforms.
Organizations that combine clinical evidence, interoperability, AI governance, data security, and region-specific commercialization will be best positioned to lead. The strongest opportunities will emerge where breast imaging solutions improve access, accuracy, efficiency, patient experience, and continuity from screening through diagnosis, biopsy, treatment planning, and surveillance.